The report analyzes and presents an overview of “ Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016 “ worldwide.
GlobalData’s clinical trial report, Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016″ provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Download Sample copy of this Report @
http://www.marketresearchreports.biz/sample/sample/821922
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Reasons to buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Glioblastoma Multiforme (GBM) 29
Aug 04, 2016: DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 29
Jul 25, 2016: ImmunoCellular Therapeutics Provides Update on Lead Cancer Immunotherapy ICT-107 29
Jul 15, 2016: ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 30
Jul 12, 2016: VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 30
Jun 28, 2016: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 31
Jun 07, 2016: ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma 31
Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting 32
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact us:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948